Elicio Therapeutics (ELTX) Non-Current Assets (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Non-Current Assets data on file, last reported at $6.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 10.41% year-over-year to $6.5 million; the trailing twelve-month figure through Mar 2026 stood at $26.8 million (down 15.04% YoY), and the FY2025 full-year result was $6.6 million, down 12.48% from the prior year.
• Non-Current Assets for Q1 2026 stood at $6.5 million, down from $6.6 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $11.9 million in Q4 2022 and bottomed at $1.1 million in Q1 2023.
• The 5-year median for Non-Current Assets is $7.2 million (2025), against an average of $7.6 million.
• The widest annual swing landed in 2023, when Non-Current Assets tumbled 77.29%; it then soared 807.89% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $11.9 million in 2022, then slipped by 9.62% to $10.8 million in 2023, then slumped by 30.68% to $7.5 million in 2024, then slipped by 12.48% to $6.6 million in 2025, then declined by 0.95% to $6.5 million in 2026.
• The last three Non-Current Assets figures came in at $6.5 million (Q1 2026), $6.6 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.

Peer Comparison